Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.

Kuwahara M, Hasumi S, Mandai S, Tanaka T, Shikuma S, Akita W, Mori Y, Sasaki S.

Clin Exp Nephrol. 2014 Oct;18(5):755-62. doi: 10.1007/s10157-013-0919-0. Epub 2013 Dec 7.

PMID:
24317507
2.

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF.

Cochrane Database Syst Rev. 2014 Dec 8;(12):CD010590. doi: 10.1002/14651858.CD010590.pub2. Review.

PMID:
25486075
3.

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.

Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2017 Aug 7;8:CD009904. doi: 10.1002/14651858.CD009904.pub2. Review.

PMID:
28782299
4.

Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.

Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.

J Manag Care Pharm. 2009 Nov-Dec;15(9):741-50.

5.

Darbepoetin for the anaemia of chronic kidney disease.

Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF.

Cochrane Database Syst Rev. 2014 Mar 31;(3):CD009297. doi: 10.1002/14651858.CD009297.pub2. Review.

PMID:
24683046
6.

Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.

Kuwahara M, Mandai S, Kasagi Y, Kusaka K, Tanaka T, Shikuma S, Akita W.

Clin Exp Nephrol. 2015 Aug;19(4):598-605. doi: 10.1007/s10157-014-1023-9. Epub 2014 Sep 3.

PMID:
25183365
7.

Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study.

Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB.

Clin Drug Investig. 2011;31(2):113-20. doi: 10.2165/11584460-000000000-00000.

PMID:
21067252
8.

Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.

Alsalimy N, Awaisu A.

Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7. Review.

PMID:
25288147
9.

Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.

Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.

J Manag Care Pharm. 2008 Nov-Dec;14(9):858-69.

10.

Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.

Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, Van Belle S.

Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18. Review.

11.

Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.

Otsuka T, Sakai Y, Yui S, Sukegawa M, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Tsuruoka S.

J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21.

12.

Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.

Wilhelm-Leen ER, Winkelmayer WC.

Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28. Review.

13.

Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.

Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC.

J Nephrol. 2008 Jul-Aug;21(4):543-9.

PMID:
18651544
14.

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.

Am J Kidney Dis. 2013 Jan;61(1):44-56. doi: 10.1053/j.ajkd.2012.07.014. Epub 2012 Aug 22.

15.

Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.

Choi P, Farouk M, Manamley N, Addison J.

Adv Ther. 2013 Nov;30(11):1007-17. doi: 10.1007/s12325-013-0063-y. Epub 2013 Oct 31.

16.

Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.

Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.

Curr Med Res Opin. 2006 Oct;22(10):2023-30.

PMID:
17022861
17.

Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.

Liao SC, Hung CC, Lee CT, Lee CH, Lee CC, Lin CL, Sun CY, Cheng BC, Yang CC, Wu CH, Chen JB.

Ther Apher Dial. 2016 Aug;20(4):400-7. doi: 10.1111/1744-9987.12401. Epub 2016 Apr 5.

PMID:
27060362
18.

Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.

Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, Brookhart MA, Goldstein BA.

Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339. Epub 2015 May 2.

19.

Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.

Siegel J, Jorgenson J, Johnson PE, Brophy DF, Comstock T, Feng A, Audhya P.

Am J Health Syst Pharm. 2008 Sep 15;65(18):1711-9. doi: 10.2146/ajhp070526.

PMID:
18768997
20.

Supplemental Content

Support Center